Keywords
How to Cite
Abstract
Genitourinary Syndrome of Menopause (GMS) is one of the most frequent reasons for women's consultation in gynecology, presenting with a prevalence of 50 to 80% in postmenopausal women. Therefore, it is necessary to offer patients a safe, effective, and time-adherent treatment. This work proposes to compare the effectiveness and safety of the 10,600nm CO2 laser and 2,940nm Er:YAG. in the treatment of symptoms related to GMS. For this, vaginal health, urinary incontinence, sexual function, biopsy analysis, and cytology were comprehensively evaluated before and after applying three treatment sessions with the CO2 and Er:YAG laser, independently, to two groups. of women in private gynecology practice. Good tolerance of the intervention and high satisfaction rates were obtained for both protocols (CO2 and Er:YAG), in addition to similar success values in increasing (p<0.05) vaginal health and decreasing SUI. , with an improvement in atrophic epithelial tissue. Compared with the Er:YAG laser, the CO2 laser achieved better results in terms of reducing the severity of clinical symptoms, a 39% increase in sexual function, a greater number of young fibroblasts, and neovascularization in the epithelium. None of the described protocols presented adverse effects during and after application in patients with SGM. In conclusion, both laser platforms are a safe, effective, and well-tolerated outpatient alternative for vaginal functional restoration in the treatment of GMS.
References
Portman DJ, Gass MLS, Kingsberg S, Archer D, Bachmann G, Burrows L, et al. Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American Menopause Society. Menopause [Internet]. 2014 [cited 2024 Apr 6];21(10):1063–8. Available from: https://academic.oup.com/jsm/article-abstract/11/12/2865/6958055
Moral E, Delgado JL, Carmona F, Caballero B, Guillán C, González PM, et al. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric [Internet]. 2018 Mar 4 [cited 2024 Apr 6];21(2):167–73. Available from: https://www.tandfonline.com/doi/abs/10.1080/13697137.2017.1421921
La Veglia R, Parilli M. Consideraciones generales. Rev Obs Ginecol Venez [Internet]. 2018 [cited 2024 Apr 6];78(Supl 1):S4–12. Available from: https://sogvzla.org/wp-content/uploads/2022/04/5Capitulo.pdf
De Landsheere L, Munaut C, Nusgens B, Maillard C, Rubod C, Nisolle M, et al. Histology of the vaginal wall in women with pelvic organ prolapse: A literature review. Int Urogynecol J Pelvic Floor Dysfunct [Internet]. 2013 Dec [cited 2024 Apr 6];24(12):2011–20. Available from: https://link.springer.com/article/10.1007/s00192-013-2111-1
Tadir Y, Gaspar A, Lev-Sagie A, Alexiades M, Alinsod R, Bader A, et al. Light and energy based therapeutics for genitourinary syndrome of menopause: Consensus and controversies. Lasers Surg Med [Internet]. 2017 [cited 2024 Apr 6];49(2):137–59. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/lsm.22637
Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol [Internet]. 2016 [cited 2024 Apr 6];215(6):704–11. Available from: https://www.sciencedirect.com/science/article/pii/S000293781630518X
Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. Vulvar and vaginal atrophy in four European countries: Evidence from the European REVIVE Survey. Climacteric [Internet]. 2016 Mar 3 [cited 2024 Apr 6];19(2):188–97. Available from: https://www.tandfonline.com/doi/abs/10.3109/13697137.2015.1107039
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2024 Revista Iberoaméricana de Láser Médico